Evidence guide · UK
Glucosamine and dementia: what the Florida study shows, why other data point the other way, and the weak case for joints
A Nature Metabolism study linked glucosamine use with faster progression and higher mortality in people who already had mild cognitive impairment or dementia. What it shows, why UK Biobank data differ, and what trials say about joints.
Review type: research summary. This page summarises published research and product labels, cited below.
Glucosamine is a popular joint supplement. A University of Florida study published in Nature Metabolism on 9 June 2026 linked it to worse outcomes in people who already have mild cognitive impairment or dementia: in health records, glucosamine use was associated with a 25% increase in the proportion of people with mild cognitive impairment (MCI) who progressed to dementia, and with a 25% higher mortality risk in people with Alzheimer's disease and related dementias.
Short answer: this is a safety signal, not proof of harm. The human data are observational, and the authors say a clinical trial is needed. Large UK Biobank studies of people without dementia found glucosamine use linked to a lower or unchanged dementia risk, and those studies have their own known bias. What is clearer is that glucosamine's benefit for joint pain is uncertain, and NICE advises against offering it for osteoarthritis. If you have MCI or dementia and take glucosamine, that combination is worth raising with your doctor.
What the Florida study did
The main work is laboratory research on how the Alzheimer's brain handles sugar chains attached to proteins, a process called N-glycosylation. Using imaging of post-mortem human brain tissue and mouse models, the team reports that brains with Alzheimer's disease carry significantly higher levels of these sugar structures than healthy brains, and calls this hyperglycosylation a driver of the disease. Glucosamine entered the picture because it feeds the pathway that builds those sugar chains and can cross the blood-brain barrier.
- Mice: female 5xFAD mice, a model of Alzheimer's-type pathology, aged eight to nine months, were given glucosamine sulphate by mouth at 457 mg per kg of body weight a day for two weeks. The authors calculated this dose from a human dose of about 2,500 mg a day. Brain glycan levels rose and social recognition memory got worse, in six treated mice compared with seven controls. Plaque counts and markers of reactive astrocytes did not change.
- Healthy mice: the same glucosamine regimen in normal mice did not raise brain glycan levels or impair memory. The authors read this as a sign that the effect depends on the brain already being diseased.
- Health records: the team used University of Florida Health records from 2012 to 2024, covering 24,481 people with Alzheimer's disease and related dementias and 41,884 people with MCI, with a median follow-up of 1,835 days (about five years). The authors report that about 8% of patients across the diagnostic groups were classed as users (1,896 with dementia and 2,750 with MCI). Exposure was flagged by keyword matching in clinical notes. The paper also describes documented glucosamine use for at least one year after a dementia diagnosis, taken from physician notes and prescription records.
- Results: after matching users with non-users on age, sex and demographic variables, glucosamine use was associated with a 25% increase in mortality risk among people with dementia (P = 0.0023) and a 25% increase in the proportion of people with MCI who progressed to dementia. Survival in the MCI group did not differ significantly.
What it cannot show
The University of Florida describes the results as preliminary and says they require validation in a human clinical trial. Co-author Matthew Gentry put it this way: "The electronic health record data are very provocative. While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention."
- The records do not give the dose or the product, and a note or a prescription does not show how much each person actually took.
- The methods describe propensity-score matching on age and on demographic variables, and the results also name sex. Glucosamine is commonly used for joint health, and the matching step as described did not account for arthritis, pain, mobility or other medicines.
- The human-equivalent dose, about 2,500 mg a day, was higher than the 1,500 mg of glucosamine hydrochloride a day used in the US GAIT trial, the treatment lasted two weeks, and the memory result rests on 13 mice of one sex in one model.
- One author reports research support and research compounds from drug companies, and consultancy fees from drug companies and a patient foundation. Another author receives a book royalty. The study was supported by US National Institutes of Health grants.
Other studies point the other way
Several analyses of UK Biobank, a large British cohort, looked at people without dementia at the start. A 2022 study of 495,942 participants found habitual glucosamine use linked to a lower risk of dementia (hazard ratio 0.87). A 2023 study reported a lower risk of all-cause dementia (0.84) and of Alzheimer's disease (0.83). Another 2023 analysis of 214,945 people over 60 found a lower risk of vascular dementia (0.82) but no significant link with Alzheimer's disease (1.02). A 2024 analysis of about 290,000 people found no association with dementia (1.06, not significant).
These cohorts have a known weakness. A 2022 paper in Pharmacoepidemiology and Drug Safety showed that observational studies of glucosamine reporting lower death and cancer rates were affected by selection bias, because people had started glucosamine before joining the cohort and had agreed to take part. Using the UK Biobank mortality study as an example, the authors showed how a true rate ratio of 1.0 could appear as 0.82. Neither the reassuring cohorts nor the Florida records can settle whether glucosamine helps or harms the brain. The populations also differ: UK Biobank enrolled people without dementia, while the Florida signal appeared in people already diagnosed with MCI or dementia.
Does glucosamine help joints?
The evidence is weak and inconsistent. In the US GAIT trial, 1,583 people with painful knee osteoarthritis took 1,500 mg of glucosamine hydrochloride a day, 1,200 mg of chondroitin sulphate, both, the painkiller celecoxib or a placebo for 24 weeks. Glucosamine was not significantly better than placebo: its response rate was 3.9 percentage points higher (P = 0.30), while celecoxib's was 10.0 points higher. An exploratory analysis suggested a possible benefit for the combination in people with moderate to severe pain. In a two-year GAIT follow-up of 662 people, no treatment achieved a clinically important difference in pain or function compared with placebo.
Guidelines disagree. NICE tells clinicians in England not to offer glucosamine to manage osteoarthritis and, if a person asks about it, to explain that there is no strong evidence of benefit. According to the NIH National Center for Complementary and Integrative Health, the 2019 American College of Rheumatology and Arthritis Foundation guideline strongly recommends against glucosamine for knee osteoarthritis, as does the 2019 Osteoarthritis Research Society International guideline, while a 2021 American Academy of Orthopaedic Surgeons guideline lists it among supplements that may help, with a caution that the evidence is inconsistent. In 2012 the European Food Safety Authority concluded that a cause-and-effect relationship had not been established between glucosamine and maintenance of normal joint cartilage in people without osteoarthritis.
Safety
The NIH National Center for Complementary and Integrative Health says large studies of glucosamine for osteoarthritis have not identified major safety problems, but glucosamine may raise blood sugar in some people, and glucosamine and chondroitin have been associated with an increased risk of bleeding in people taking warfarin. In 2011 the European Food Safety Authority reviewed more than 40 case reports in which the blood-clotting measure INR rose after people on coumarin anticoagulants, mostly warfarin, started glucosamine, sometimes with bleeding. It concluded that there is a risk of interaction in some people but that the level of risk cannot be worked out from the data. Little is known about glucosamine in pregnancy or breastfeeding.
Our view
- The Florida paper is mainly brain biology. The glucosamine findings are a secondary test of the idea, with a small mouse experiment and health-record associations that cannot prove cause and effect.
- It does not show that glucosamine causes Alzheimer's disease. In people without dementia, the large cohorts found a lower or unchanged risk, and those results may be flattered by the kind of selection bias described above.
- The signal matters most for one group: people already diagnosed with MCI or dementia. For them, a supplement with uncertain joint benefit and a possible downside is worth reviewing with a doctor.
- For everyone else, the stronger reason to question glucosamine is the joint evidence itself: GAIT was negative on its main outcome, and NICE does not recommend it.
- If you take warfarin or another coumarin anticoagulant, or you are watching your blood sugar, tell your doctor or pharmacist before starting glucosamine.
UK rules
In the UK, food supplements are regulated as food, not as medicines, and are not intended to treat or prevent disease. In Great Britain, health claims on food must be authorised, and the European Food Safety Authority opinion above found that a cause-and-effect relationship had not been established for glucosamine and maintenance of normal joint cartilage. NICE guidance on osteoarthritis advises against offering glucosamine. In England, Wales and Northern Ireland, report a food safety or hygiene problem to the local authority food safety team where the business is located. In England and Wales, report misleading labelling or health claims to Trading Standards. In Scotland and Northern Ireland, report those labelling and claims problems to the local food safety team.
FAQ
Should I stop glucosamine if I have memory problems?
Talk to the doctor who manages your care before changing anything. The Florida study links glucosamine with faster progression in people with MCI and higher mortality in people with dementia, but it cannot show cause and effect, and the authors are calling for a trial.
Does glucosamine cause dementia in healthy people?
That is not shown. The Florida study looked at people already diagnosed with MCI or dementia. In UK Biobank studies of people without dementia, glucosamine use was linked to a lower or unchanged dementia risk, though bias in those studies means this is not proof of protection either.
Is chondroitin affected too?
The Florida study looked at glucosamine, which feeds the sugar-building pathway it studied. It did not report results for chondroitin, so the findings should not be assumed to apply to it.
Where does glucosamine come from?
According to the University of Florida, supplement glucosamine can be made from shellfish shells or from corn. Check the label for the source.
Sources
These are the documents this page relies on.
- Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nat Metab. 2026;8(6):1410-1425 (online 9 June 2026)Nature Metabolism (PubMed 42265388)
- Study links joint pain supplement to accelerating dementiaUniversity of Florida Health
- Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomization study. BMC Med. 2023;21(1):114BMC Medicine (PubMed 36978077)
- The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study. Alzheimers Res Ther. 2022;14(1):184Alzheimer's Research & Therapy (PubMed 36514123)
- Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population. Alzheimers Res Ther. 2023;15(1):152Alzheimer's Research & Therapy (PubMed 37689747)
- No associations between glucosamine supplementation and dementia or Parkinson's disease: findings from a large prospective cohort study. J Gerontol A Biol Sci Med Sci. 2024;79(2):glad123Journals of Gerontology: Series A (PubMed 37158699)
- Glucosamine and lower mortality and cancer incidence: selection bias in the observational studies. Pharmacoepidemiol Drug Saf. 2022;31(12):1272-1279Pharmacoepidemiology and Drug Safety (PubMed 36029480)
- Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808New England Journal of Medicine (PubMed 16495392)
- Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010;69(8):1459-1464Annals of the Rheumatic Diseases (PubMed 20525840)
- Glucosamine and chondroitin for osteoarthritis: what you need to knowNIH National Center for Complementary and Integrative Health
- Scientific Opinion on the substantiation of a health claim related to glucosamine and maintenance of normal joint cartilage pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10(5):2691European Food Safety Authority
- Statement on the safety of glucosamine for patients receiving coumarin anticoagulants. EFSA Journal 2011;9(12):2473European Food Safety Authority
- Osteoarthritis in over 16s: diagnosis and management (NG226), recommendationsNational Institute for Health and Care Excellence
- Food supplementsFood Standards Agency
- Great Britain nutrition and health claims (NHC) registerDepartment of Health and Social Care
- How to report a food safety or hygiene issueFood Standards Agency
- Report misleading labellingFood Standards Agency